Impressive clinical response following combined BRAF and MEK inhibition in a low-grade serous ovarian carcinoma patient with a BRAF V600E mutation

Impressive clinical response following combined BRAF and MEK inhibition in a low-grade serous ovarian carcinoma patient with a BRAF V600E mutation

Introduction: Low-grade serous ovarian cancer (LGSOC) accounting for less than 10% of all serous ovary cancers. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinase (...

Full description

Bibliographic Details
Main Authors: Anna Rodzajewska, Weronika Kuryło, Katarzyna Szklener
Format: Article
Language:English
Published: Kazimierz Wielki University 2023-08-01
Series:Journal of Education, Health and Sport
Subjects:
dabrafenib
trametinib
V600E mutation
low-grade serous ovarian cancer
next generation sequencing
targeted therapy
Online Access:https://apcz.umk.pl/JEHS/article/view/44940

Internet

https://apcz.umk.pl/JEHS/article/view/44940

Similar Items